4 January 2024 in Cell Death & Disease
SMSabine Eberhart Meessen
+7
Manipulation of the subcellular localization of transcription factors by preventing their shuttling via the nuclear pore complex (NPC) emerges as a novel therapeutic strategy against cancer. One transmembrane component of the NPC is POM121, encoded by a tandem gene locus POM121A/C on chromosome 7. Overexpression of POM121 is associated with metabolic diseases (e.g., diabetes) and unfavorable clinical outcome in patients with colorectal cancer (CRC). Peroxisome proliferator-activated receptor-gamma (PPARγ) is a transcription factor with anti-diabetic and anti-tumoral efficacy. It is inhibited by export from the nucleus to the cytosol via the RAS-RAF-MEK1/2-ERK1/2 signaling pathway, a major oncogenic driver of CRC. We therefore hypothesized that POM121 participates in the transport of PPARγ across the NPC to regulate its transcriptional activity on genes involved in metabolic and tumor control. We found that POM121A/C mRNA was enriched and POM121 protein co-expressed with PPARγ in tissues from CRC patients conferring poor prognosis. Its interactome was predicted to include proteins responsible for tumor metabolism and immunity, and in-silico modeling provided insights into potential 3D structures of POM121. A peptide region downstream of the nuclear localization sequence (NLS) of POM121 was identified as a cytoplasmic interactor of PPARγ. POM121 positivity correlated with the cytoplasmic localization of PPARγ in patients with KRAS mutant CRC. In contrast, POM121A/C silencing by CRISPR/Cas9 sgRNA or siRNA enforced nuclear accumulation of PPARγ and activated PPARγ target genes promoting lipid metabolism and cell cycle arrest resulting in reduced proliferation of human CRC cells. Our data suggest the POM121-PPARγ axis as a potential drugable target in CRC.
10 August 2022 in Oncogene
4 September 2025 in Annals of Surgical Oncology
Background: Interest in evaluating neoadjuvant immunotherapy for stage IIB/IIC melanoma is growing, but studies assessing long-term outcomes generally report data based on pathologic stage after sentinel lymph node microstaging. This study therefore aimed to characterize real-world recurrence patterns and survival specifically in clinical stage IIB/IIC melanoma to contextualize outcomes for selection of patients to undergo neoadjuvant immunotherapy. Methods: This single-institution retrospective cohort study included patients who received a diagnosis of American Joint Committee on Cancer eighth-edition clinical stage IIB/IIC cutaneous melanoma from 2006 to 2019. Factors associated with recurrence were analyzed using univariable analysis and multivariable Cox proportional hazards analysis. Recurrence-free survival (RFS), melanoma-specific survival (MSS), and overall survival (OS) were analyzed using the Kaplan–Meier method. Results: The inclusion criteria were met by 229 patients, of whom 152 (66%) were male and 208 (91%) were white. The median follow-up time was 64 months (interquartile range [IQR] 29–105 months). Overall, 101 (44%) patients experienced a recurrence, with a median time-to-recurrence of 15.3 months (IQR 8–31 months). The estimated 2-year RFS, MSS, and OS were 69%, 91%, and 87%, respectively. The presence of pre-surgical lymphovascular invasion (hazard ratio [HR] 1.764; p = 0.018) was associated with increased risk of recurrence. Conclusion: This single-institution retrospective cohort study of patients with clinical stage IIB/IIC melanoma found a 2-year RFS of 69%. The presence of pre-surgical lymphovascular invasion was significantly associated with recurrence in this population. These data can help guide clinicians and researchers in the design and assessment of future studies evaluating neoadjuvant therapy in clinical stage IIB/IIC melanoma and in optimizing patient selection.
27 December 2024 in Surgical Clinics of North America
13 May 2025 in Journal of Surgical Oncology
Background: Neoadjuvant immunotherapy (NIT) with checkpoint blockade has been increasingly studied for soft tissue sarcomas, however, survival outcomes data are limited, and dedifferentiated liposarcoma (DDLPS) histology remains underrepresented in recent trial cohorts. We assessed the impact of NIT with or without radiation therapy (RT) on overall survival (OS) for resectable DDLPS.Methods: The National Cancer Database (NCDB) was used to identify patients diagnosed with nonmetastatic DDLPS who received NIT and underwent surgical resection between 2016 and 2022. Primary outcome was 5‐year OS.Results: A total of 3414 patients with DDLPS met the inclusion criteria and NIT was administered to 31 (1%) patients. Factors associated with receipt of NIT were receipt of neoadjuvant RT (NRT, odds ratio [OR]: 5.75, p < 0.001) and male sex (OR: 3.33, p = 0.036). NIT was associated with a hazard ratio (HR) for mortality of 0.89 (p = 0.786). No difference was found in 5‐year OS in the overall cohort (NIT 72% vs. 61% no NIT, p = 0.320) or in the propensity‐matched cohort (68% vs. 65%, p = 0.848). Subanalysis between NIT with NRT versus NRT‐only also did not find any significant difference in 5‐year OS (88% vs. 59%, p = 0.331).Conclusion: In this retrospective NCDB analysis of patients with resectable DDLPS, administration of NIT did not significantly affect OS.